Background: The usefulness of telemedicine in the management of the coronavirus disease 2019 (COVID-19) pandemic has not been evaluated. Methods: We conducted a descriptive study of the process of recruitment and follow-up of patients using a telemedicine tool (TELEA) in the management of patients at risk, in a rural environment with a dispersed population in Lugo in north western Spain. Results: A large number of patients diagnosed with COVID-19 infection (N = 545) were evaluated. Of this group, 275 had comorbidities and were enrolled in the program, with a mean age of 57.6 ± 16.3 years, 43.1% male. The risk factors were hypertension (38%), diabetes (16%), asthma (9.5%), heart disease (8.8%), and immunosuppression (5.1%). Patients were followed through the platform with daily control of symptoms and vital signs. Only 8% were admitted to the hospital, 5.1% on a scheduled basis and 2.9% through the emergency room. Conclusion: The telemedicine tool TELEA is useful for the management of high-risk patients with COVID-19.
Background: The usefulness of telemedicine in the management of the coronavirus disease 2019 (COVID-19) pandemic has not been evaluated. Methods: We conducted a descriptive study of the process of recruitment and follow-up of patients using a telemedicine tool (TELEA) in the management of patients at risk, in a rural environment with a dispersed population in Lugo in north western Spain. Results: A large number of patients diagnosed with COVID-19infection (N = 545) were evaluated. Of this group, 275 had comorbidities and were enrolled in the program, with a mean age of 57.6 ± 16.3 years, 43.1% male. The risk factors were hypertension (38%), diabetes (16%), asthma (9.5%), heart disease (8.8%), and immunosuppression (5.1%). Patients were followed through the platform with daily control of symptoms and vital signs. Only 8% were admitted to the hospital, 5.1% on a scheduled basis and 2.9% through the emergency room. Conclusion: The telemedicine tool TELEA is useful for the management of high-risk patients with COVID-19.
Authors: Francisco Gude; Vanessa Riveiro; Nuria Rodríguez-Núñez; Jorge Ricoy; Óscar Lado-Baleato; Tamara Lourido; Carlos Rábade; Adriana Lama; Ana Casal; Romina Abelleira-París; Lucía Ferreiro; Juan Suárez-Antelo; María E Toubes; Cristina Pou; Manuel Taboada-Muñiz; Felipe Calle-Velles; Plácido Mayán-Conesa; María L Pérez Del Molino; Cristóbal Galbán-Rodríguez; Julián Álvarez-Escudero; Carmen Beceiro-Abad; Sonia Molinos-Castro; Néstor Agra-Vázquez; María Pazo-Núñez; Emilio Páez-Guillán; Pablo Varela-García; Carmen Martínez-Rey; Hadrián Pernas-Pardavila; María J Domínguez-Santalla; Martín Vidal-Vázquez; Ana T Marques-Afonso; Arturo González-Quintela; José R González-Juanatey; Antonio Pose; Luis Valdés Journal: Sci Rep Date: 2020-11-13 Impact factor: 4.379
Authors: Francisco Gude-Sampedro; Carmen Fernández-Merino; Lucía Ferreiro; Óscar Lado-Baleato; Jenifer Espasandín-Domínguez; Xurxo Hervada; Carmen M Cadarso; Luis Valdés Journal: Int J Epidemiol Date: 2021-03-03 Impact factor: 7.196
Authors: Sharareh R Niakan Kalhori; Kambiz Bahaadinbeigy; Kolsoum Deldar; Marsa Gholamzadeh; Sadrieh Hajesmaeel-Gohari; Seyed Mohammad Ayyoubzadeh Journal: J Med Internet Res Date: 2021-03-10 Impact factor: 5.428
Authors: Sonia Herrero Martín; Javier Hueto Pérez de Heredia; Alberto Cuesta Remón; Marisol Gómez Fernández; María M Antón; Juan Cabasés; Ruth García Rey; Pilar Cebollero Rivas Journal: Arch Bronconeumol Date: 2021-06-16 Impact factor: 6.333